Oral 5‐ASA showed no clear difference in failure to induce global or clinical improvement compared with SASP (high certainty).
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with sulfasalazine (moderate certainty).
Oral 5‐aminosalicylic acid probably leads to higher exclusion/withdrawal after entry compared with sulfasalazine (moderate certainty).
Oral 5‐aminosalicylic acid leads to higher failure to maintain clinical or endoscopic remission compared with sulfasalazine (high certainty).
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with sulfasalazine (moderate certainty).
Probiotics may leads to higher clinical remission compared with placebo (low certainty).
The review found no eligible studies for this question.
Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) may leads to higher remission compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Probiotics may leads to higher disease improvement (based on clinical scores) compared with placebo (low certainty).
It is very uncertain whether probiotics changes minor adverse events compared with placebo (very low certainty).
It is very uncertain whether probiotics changes serious adverse events compared with placebo (very low certainty).
Probiotics showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
Probiotics showed no clear difference in clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
It is very uncertain whether probiotics changes minor adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).